Hypothesis

Senescent enteroendocrine L-cells are not inert debris; they actively secrete a senescence‑associated secretory phenotype (SASP) packaged into exosomes that suppress proliferation of neighboring L‑cell progenitors and fine‑tune GLP‑1 release in the duodenal mucosa. Consequently, removing these cells with senolytics will lift the proliferative brake, expand the L‑cell pool, but disrupt the paracrine GLP‑1 signaling network, leading to altered glucose homeostasis.

Mechanistic rationale

1. SASP composition in enteroendocrine L‑cells – Drawing from pancreatic β‑cell data, senescent endocrine cells enrich SASP proteins involved in inflammation, stress response, and extracellular vesicle pathways (1). We predict that senescent L‑cells similarly load exosomes with TGF‑β, IL‑6, and specific microRNAs (e.g., miR‑29 family) that inhibit Wnt/β‑catenin signaling in stem/progenitor cells.
2. Paracrine GLP‑1 dominance – Only ~15 % of secreted GLP‑1 reaches the circulation; the majority acts locally (4). Thus, any alteration in the mucosal microenvironment will have outsized effects on nutrient‑induced GLP‑1 pulses.
3. Adaptive coordinator role – SASP can enforce senescence in adjacent cells while also recruiting immune modulators that preserve tissue integrity (2). In the intestine, this duality may prevent hyperplastic expansion of L‑cells after injury, acting as a "hostage negotiator" that balances repair with restraint.
4. Plasticity of L‑cell function – High‑fat diet impairs GLP‑1 release, showing that L‑cell output is responsive to extrinsic cues (5). SASP factors could serve as one such cue, adjusting secretory capacity in metabolic stress.

Testable predictions

• Prediction 1: In aged mice, duodenal tissue will show a higher proportion of chromogranin A⁺/p16⁺ senescent L‑cells compared with young mice.
• Prediction 2: Exosomes isolated from senescent L‑cell cultures will reduce Ki‑67⁺ proliferation in murine intestinal organoids and decrease β‑catenin nuclear translocation.
• Prediction 3: Senolytic clearance (e.g., navitoclax) in aged mice will increase L‑cell progenitor proliferation (Ki‑67⁺/chromogranin A⁺) but diminish basal and glucose‑stimulated GLP‑1 release measured in mucosal biopsies.
• Prediction 4: Supplementation of senescent‑L‑cell‑derived exosomes to senolytic‑treated mice will restore normal GLP‑1 pulsatility and improve glucose tolerance.

Experimental approach

1. Cell isolation & senescence induction – Harvest duodenal L‑cells from young and aged mice; induce senescence ex vivo with low‑dose doxorubicin; validate by p16^Ink4a^ and SA‑β‑gal staining.
2. Exosome profiling – Ultracentrifuge conditioned media; perform proteomics and small‑RNA sequencing to identify SASP cargo (focus on TGF‑β, IL‑6, miR‑29).
3. Functional assays – Treat intestinal organoids with purified exosomes; assess proliferation (EdU incorporation), differentiation (chromogranin A, proglucagon), and GLP‑1 secretion (ELISA) after glucose or fatty acid challenge.
4. In vivo intervention – Administer senolytic or vehicle to aged cohorts; after 2 weeks, isolate duodenal crypts for flow cytometry (p16⁺/chromogranin A⁺) and measure GLP‑1 dynamics during oral glucose tolerance tests.
5. Rescue – Inject isolated exosomes intravenously or via rectal enema to senolytic‑treated mice; repeat GLP‑1 and metabolic phenotyping.

If predictions hold, the data would reframe senescent enteroendocrine cells as active negotiators that restrain proliferative expansion while sustaining paracrine GLP‑1 signaling. Failure to observe the predicted exosome‑mediated proliferation suppression or the glucose‑intolerant phenotype post‑senolysis would falsify the hypothesis.